Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer by 김혜련 et al.
CLINICAL CANCER RESEARCH | TRANSLATIONAL CANCER MECHANISMS AND THERAPY
Repotrectinib Exhibits Potent Antitumor Activity in
Treatment-Naïve and Solvent-Front–Mutant
ROS1-Rearranged Non–Small Cell Lung Cancer A  C
Mi Ran Yun1,2, Dong Hwi Kim1, Seok-Young Kim1, Hyeong-Seok Joo1, You Won Lee2, Hun Mi Choi2,
Chae Won Park2, Seong Gu Heo3, Han Na Kang1,2, Sung Sook Lee4, Adam J. Schoenfeld5,




Purpose: Although first-line crizotinib treatment leads to
clinical benefit in ROS1þ lung cancer, high prevalence of crizo-
tinib-resistant ROS1-G2032R (ROS1G2032R) mutation and pro-
gression in the central nervous system (CNS) represents a
therapeutic challenge. Here, we investigated the antitumor activ-
ity of repotrectinib, a novel next-generation ROS1/TRK/ALK-
tyrosine kinase inhibitor (TKI) in ROS1þ patient-derived pre-
clinical models.
Experimental Design: Antitumor activity of repotrectinib was
evaluated in ROS1þ patient-derived preclinical models including
treatment-naïve and ROS1G2032R models and was further dem-
onstrated in patients enrolled in an on-going phase I/II clinical
trial (NCT03093116). Intracranial antitumor activity of repotrec-
tinib was evaluated in a brain-metastasis mouse model.
Results: Repotrectinib potently inhibited in vitro and in vivo
tumor growth and ROS1 downstream signal in treatment-naïve
YU1078 compared with clinically available crizotinib, ceritinib,
and entrectinib. Despite comparable tumor regression between
repotrectinib and lorlatinib in YU1078-derived xenograft model,
repotrectinib markedly delayed the onset of tumor recurrence
following drug withdrawal. Moreover, repotrectinib induced pro-
found antitumor activity in the CNS with efficient blood–brain
barrier penetrating properties. Notably, repotrectinib showed
selective and potent in vitro and in vivo activity against
ROS1G2032R. These findings were supported by systemic and
intracranial activity of repotrectinib observed in patients enrolled
in the on-going clinical trial.
Conclusions: Repotrectinib is a novel next-generation
ROS1-TKI with improved potency and selectivity against treat-
ment-naïve and ROS1G2032R with efficient CNS penetration. Our
findings suggest that repotrectinib can be effective both as first-
line and after progression to prior ROS1-TKI.
Introduction
Chromosomal rearrangements in ros proto-oncogene1 (ROS1)
gene defines a distinct molecular subset in non–small cell lung cancer
(NSCLC; refs. 1–3). The development of ROS1 targeted agents and the
approval of crizotinib as a standard first-line therapy has transformed
the course of disease for ROS1-driven NSCLC. Although ROS1
tyrosine kinase inhibitors (TKI) markedly improve clinical outcomes,
patients inevitably relapse within a few years, and subsequent therapy
overcoming acquired resistance remains limited (3, 4). Several major
resistance mechanisms to ROS1-TKIs have been identified, including
secondary mutations within the ROS1 kinase domain and activation
of bypass signaling pathways (1, 5). Approximately 50% to 60%
crizotinib-resistant mutations are found within the ROS1 kinase, of
which ROS1-G2032R (ROS1G2032R) solvent-front mutation (SFM) is
the most common and recalcitrant-resistant mutation. These reports
highlight the importance of developing novel ROS1 inhibitors with
potent activity against G2032R (1, 6).
The brain is considered amajor pharmacologic sanctuary because of
the blood–brain barrier (BBB; refs. 7, 8). Indeed, approximately 50% of
patients treatedwithROS1-TKIs experience disease progression due to
central nervous system (CNS) metastases (7, 9). The high incidence of
CNS progression and poor prognosis in ROS1-rearranged NSCLC
indicates an unmet clinical need for novel ROS1-TKIs with improved
efficacy against brain lesions.
Repotrectinib (TPX-0005) is a novel next-generation ROS1/TRK/
ALK-TKI specifically designed to overcome refractory SFMs, which
commonly emerge in patients with ROS1/NTRK/ALK-rearranged
malignancies who have relapsed on currently available TKIs (10).
Repotrectinib for TKI-refractory patients is currently under phase I/II
clinical trial (NCT03093116).
Existing preclinical studies in ROS1-rearranged NSCLC use a
limited number of commercial or genetically engineered cell lines.
This fails to fully encompass the genetic complexities observed in
patients, leading to discrepancies between preclinical and clinical drug
responses. Here, we evaluated the antitumor activity of repotrectinib in
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ROS1þ NSCLC patient-derived cell lines (PDC) and patient-derived
xenograft (PDX) models. Moreover, we examined the intracranial
antitumor activity of repotrectinib in a brain-metastasis mouse model
developed through intracranial PDC implantation.
Materials and Methods
Patients
All patient samples were obtained from patients with ROS1 rear-
rangements before and after treatment with ROS1-TKIs at Yonsei
University Severance Hospital (Seoul, Republic of Korea). All patients
provided written informed consent. The study protocol was approved
by the Institutional Review Board of Severance Hospital (IRB no.: 4-
2016-0788). Patients treated with repotrectinib are enrolled in clinical
trial NCT-03093116. This study was conducted according to the
principles set out in the World Medical Association Declaration of
Helsinki and the United States Department of Health and Human
Services Belmont Report.
Establishment of PDCs
PDCs were established from malignant effusions of patients with
advanced lung adenocarcinoma (11). Briefly, patient pleural effusion
samples were centrifuged at 500  g for 10 minutes at 25C and
resuspended in PBS. Cells were separated with Ficoll-Paque PLUS
solution, following manufacturer's protocol. The interface containing
themononuclear cells was washed twice inHBSS and plated on collage
IV-coated plates in RPMI medium supplemented with 10% FBS. To
determine whether PDCs maintained patient characteristics, sanger
sequencing and whole-exome sequencing were performed. FACS
staining of EpCAM confirmed PDCs with over 99% cancer purity.
The following ROS1-rearranged PDCs were used: YU1078
(CD74-ROS1) and YU1079 (CD74-ROS1 G2032R) (Table 1). San-
ger-sequencing-identified fusion partners in PDCs were identical to
those identified in corresponding patient biopsies.
Establishment of PDXs
ROS1-rearranged PDX model YHIM1047 was established as pre-
viously described (Table 1; ref. 12).To generate PDC-derived tumor
xenograft models, cells (YU1078 and YU1079, 5 106 in 100 mL) were
implanted subcutaneously into the flanks of 6-week-old female nu/nu
mice. Animals were randomly divided (N¼ 5 per group) when tumor
volume reached 150 to 200 mm3. Each group received one of the
following treatments: once-daily crizotinib (50 mg/kg, every day),
ceritinib (25 mg/kg, every day), entrectinib (30 mg/kg, every day),
lorlatinib (30 mg/kg, every day), cabozantinib (30 mg/kg, every day),
and twice-daily repotrectinib (15 mg/kg, twice a day). Tumor volumes
(0.532  length  width) were measured with an electronic caliper.
Percentage change in tumor volume was calculated as follows:
(Vt  V0)/V0  100. Tumor growth inhibition (TGI) was calculated
with two formulas according to Drilon and colleagues (10). All mice
were euthanized via CO2 inhalation at the end of the experiment.
Animal procedures were approved by the Institutional Animal Care
and Use Committee (IACUC) and Animal Research Committee at
Yonsei University College of Medicine.
ROS1 TKIs
Repotrectinib (TP Therapeutics) was kindly provided by the man-
ufacturer and crizotinib, ceritinib, entrectinib, lorlatinib, and cabo-
zantinib were purchased from Selleckchem.
Cell proliferation assay
About 2,500 to 3,000 cells were seeded in 96-well plates in growth
media and incubated overnight at 37C before adding serially diluted
crizotinib, ceritinib, lorlatinib, cabozantinib, repotrectinib, and appro-
priate controls. After treating the drugs, cells were incubated at 37C
for 72 hours before performing CellTiter Glo (Promega) following the
manufacturer's protocol. Dose–response curves and IC50 values were
calculated using GraphPad Prism.
Colony-forming assays were performed by seeding the cells in six-
well plates in growth media with appropriate drug-containing media
replaced every 3 days. Plates were fixed in 4% PFA and stained in
crystal violet for 1 hour after 14 days of drug treatment.
Immunoblotting
Immunoblots were performed to determine relative phosphoryla-
tion of kinases and total protein levels of interest. Protein samples were
separated by SPS-PAGE and transferred to nitrocellulose membrane
for immunoblotting using the corresponding antibodies. P-ROS1
(T2274), ROS1, p-ERK (T202/Y204), ERK, p-AKT (S473), AKT,
p-STAT3 (T705), STAT3, and Ki67 were all purchased from Cell
Signaling Technologies. b-Actin was purchased from Sigma.
Intracranial tumor model
Intracranial tumor models were generated through implanting
YU1078-luc human NSCLC PDC into brains of female BALB/c nude
mice. After anesthetization, mice were immobilized with a stereotactic
apparatus for incision of the skull's right hemisphere. A 0.5 mm burr
hole was drilled through the right frontal lobe to implant a guide screw.
Next, 5  105 cancer cells (diluted in 5 mL PBS) were stereotactically
injected for 5 minutes into the right frontal lobe via the guided screw
and the incision was closed with surgical glue. At 13-day post-
implantation, when photon flux measured through IVIS reached
1  106 photons/second, mice were treated with a daily oral dose of
repotrectinib (15 mg/kg, twice a day), entrectinib (30 mg/kg, every
day), lorlatinib (30 mg/kg, every day), and vehicle. Brain metastatic-
tumor growth was measured using an IVIS Spectrum Xenogen
(Caliper Life Sciences).
Immunohistochemistry
IHC was performed on 4-mm-thick formalin-fixed, paraffin-
embedded (FFPE) tissue sections. Slides were baked, deparaffinized
in xylene, passed through graded alcohols, and then antigen retrieved
with 1 mmol/L EDTA, pH 8.0 at 125C for 30 seconds. Slides were
pretreated with Peroxidase Block (Dako USA) for 5 minutes, and then
washed in 50 mmol/L Tris-Cl, pH 7.4. Slides were blocked using
Translational Relevance
We report repotrectinib, a novel next-generation ROS1-TKI as a
potent inhibitor against ROS1 and recalcitrant crizotinib-resistant
G2032R mutation with efficient activity in the CNS. Repotrectinib
demonstrated potent antitumor activity compared with clinically
available crizotinib, ceritinib, entrectinib, and lorlatinib in preclin-
ical studies and showed efficient penetration of the BBB with
improved survival in brain-metastasis mousemodels. These results
were confirmed by clinical responses in patients with treatment-
naïve and crizotinib-resistant G2032R ROS1þ NSCLC. Therefore,
repotrectinib could serve as an effective first-line treatment in
ROS1þ NSCLC, including those with G2032R solvent-front
mutation.
Yun et al.
Clin Cancer Res; 26(13) July 1, 2020 CLINICAL CANCER RESEARCH3288
on September 8, 2020. © 2020 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst April 8, 2020; DOI: 10.1158/1078-0432.CCR-19-2777 
normal goat serum (Dako USA), and subsequently incubated with
anti-phosphSTAT3 mAb (Tyr705, D3A2, 1:100; CST)/anti-Ki67 anti-
body (D2H10; 1:100) for 1 hour. Slideswere thenwashed in 50mmol/L
Tris-Cl, pH7.4 and treated with Signalstain boost IHC detection
reagent [horseradish peroxidase (HRP), rabbit, #8114; CST] for 30
minutes. After further washing, immunoperoxidase staining was
developed using a 3,30diaminobenzidine (DAB) chromogen (Dako)
for 5 minutes. Slides were counterstained with hematoxylin, dehy-
drated in graded alcohol and xylene, mounted, and coverslipped.
Targeted sequencing
Comprehensive genomic profiling was performed in repeat biopsies
in 2 patients who progressed after repotrectinib. FFPE slides were
subjected to Illumina HiSeq based targeted sequencing capturing 171
cancer-related genes. Resultant reads were mapped to the human
genome reference (hg19) using Burrows-Wheeler Alignment (BWA)
followed by analysis using Genome Analysis ToolKit. Somatic muta-
tions were called using MuTect2 and annotated with Oncotator.
FoundationOne CDx (Foundation Medicine) was used to confirm
the identified genomic alterations. A whole-genome shotgun library
was constructed from 50 to 1,000 ng of extracted DNA and hybrid
capture-selected libraries were sequenced at >500 median coverage
using the Illumina HiSeq platform. All classes of cancer-related
genomic alterations (e.g., base substitutions, indels, rearrangements,
and copy-number alterations) were assayed.
Statistical analysis
Statistical analyses were performed in SPSS version 21 and
GraphPad Prism 5. All data are expressed as means  SD or SE
for three ormore independent replications. Between-group differences
were evaluated using Student t test, Mann–Whitney test, Kruskal–
Wallis with Dunn post hoc test, or ANOVAwith Tukey post hoc test, as
appropriate. Significance was set at P < 0.05.
Results
Repotrectinib potently inhibits in vitro and in vivo tumor growth
in treatment-naïve ROS1-rearranged models
In this study, we established three patient-derived preclinical
models including one treatment-naive and two ROS1-TKI–resistant
models frompatients withROS1þNSCLC (Table 1).We examined the
activities of clinically available ROS1-TKIs including crizotinib, cer-
itinib, entrectinib, lorlatinib, and repotrectinib in treatment-naive
PDC YU1078 cells generated from a patient with ROS1-TKI–naïve
NSCLC with CD74–ROS1 (35 years/female). Entrectinib (IC50,
0.052mmol/L), lorlatinib (IC50, 0.009mmol/L), and repotrectinib (IC50,
0.021 mmol/L) exhibited potent growth inhibition in YU1078 cells
compared with crizotinib (IC50, 0.156 mmol/L) and ceritinib (IC50,
0.412 mmol/L; Fig. 1A). Colony formation was significantly reduced
with lorlatinib and repotrectinib treatment compared with other TKIs
(Fig. 1B) and was accompanied by markedly suppressed ROS1 and
ERK phosphorylation levels (Fig. 1C).
Consistent with the in vitro findings, lorlatinib and repotrectinib
displayed pronounced tumor regression in subcutaneous YU1078
xenograft model with 189.2% TGI. Crizotinib and entrectinib resulted
in 150.7% and 124.9% TGI, respectively, whereas ceritinib displayed
64.7% TGI (Fig. 1D). Although tumor regression was comparable
between lorlatinib and repotrectinib, repotrectinib produced the
strongest antitumor effect, which was most apparent after drug
withdrawal. After drug withdrawal at 21 days, tumors in three of four
repotrectinib-treated mice were persistently suppressed for over
80 days. One mouse exhibited slow regrowth after 60 days post-
drug withdrawal. However, tumors in two of four lorlatinib-treated
mice abruptly regrew 10 days after drug withdrawal (Fig. 1E). To
determine whether repotrectinib is an effective subsequent treatment
option after failure to prior ROS1-TKI, we administrated repotrectinib
to tumor progressed on ceritinib. Subsequent repotrectinib treatment
prominently suppressed tumor growth where of note, upfront repo-
trectinib completely induced tumor regression (Fig. 1F). Collectively,
upfront and subsequent repotrectinib treatment demonstrated potent
TGI based on in vitro and in vivo ROS1þ preclinical models.
Repotrectinib demonstrates efficient antitumor activity in an
intracranial tumor model with a high BBB penetration profile
Lorlatinib and entrectinib have been reported to penetrate the BBB
and regress brain metastasis (13–15). We investigated the ability of
repotrectinib to penetrate BBB using an intracranial tumor model of
luciferase-transduced YU1078 cells (YU1078-luc). Compared with
vehicle and entrectinib, repotrectinib treatment significantly reduced
tumor load (as measured using photon flux) in the brain without body
weight loss (Fig. 2A and B). In addition, all repotrectinib-treated mice
survived for up to 110 days, whereas median survival of vehicle- and
entrectinib-treated mice was 49 and 57 days, respectively (Fig. 2C).
Lorlatinib showed comparable reduction of tumor load to that of
repotrectinib (Fig. 2A and B). IHC further revealed that repotrectinib
treatment completely suppressed viable brain tumors, with pro-
nounced reduction in Ki67-positive and TUNEL-positive cells com-
pared with vehicle and entrectinib treatment (Fig. 2D).
Clinical activity of repotrectinib in ROS1-TKI–naïve and
ceritinib-resistant patients
Clinical potency of repotrectinib was demonstrated in a TKI-naïve
ROS1þ patient treated with repotrectinib. A 69-year-old female CD74-
ROS1–rearranged patient was presented with liver and multiple brain
Table 1. PDCs, PDXs, and tumor biopsies from patients with ROS1-rearranged NSCLC.













Patient #1-1 PDC YU1078 CD74-ROS1 Pleural effusion WT Naïve — —
Patient #1-2 PDC YU1079 CD74-ROS1 Pleural effusion G2032R Crizotinib PR 10
Patient #2 PDX YHIM1047 CD74-ROS1 Lung G2032R Entrectinib PR 7
Patient A Patient biopsy — CD74-ROS1 Lung WT Repotrectinib PR 10
Patient B Patient biopsy — SLC34A2-ROS1 Lung WT Repotrectinib PR 10
Abbreviations: PR, partial response; WT, wild-type.
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Figure 1.
In vitro and in vivo inhibitory activity of repotrectinib in treatment-naïve ROS1þ patient-derived preclinical models. A, Cell viability assay of CD74-ROS1 YU1078
treated with ROS1-TKIs for 72 hours. B, Colony formation assays involved treatment for 14 days with the indicated dose of ROS1-TKIs; corresponding colony
quantification on the right (ANOVAwith Tukey post hoc test:  , P < 0.05 vs. crizotinib). C, Immunoblots of YU1078 after treatment with indicated crizotinib, ceritinib,
entrectinib, lorlatinib, and repotrectinib doses for 6 hours. D, Tumor growth of subcutaneous YU1078 xenograft in response to TKI treatment (Kruskal–Wallis with
Dunnpost hoc test: n.s.,P>0.05;  ,P<0.01;  ,P <0.001 vs. vehicle; ##,P<0.01 vs. ceritinib,N¼4). Correspondingwaterfall plot below represents individualmouse
response. E, Tumor growth in individual mice after withdrawal of lorlatinib and repotrectinib at 21 days and (F) treatment shift to repotrectinib in ceritinib-treated
tumors from (D). Data are mean  SD or  SE.
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Figure 2.
Antitumor efficacy of repotrectinib in ROS1þ PDC-driven intracranial tumor models. A, Representative IVIS image of intracranial YU1078-luc cells treated with
entrectinib once daily, lorlatinib once daily, and repotrectinib twice daily. Mice were orally dosed 13 days after intracranial injection. B, Average photon
count (photons/s) of intracranial metastasis over 27 days. Data are mean  SD. Significance between groups observed at 27 days (Mann–Whitney test: n.s.,
P >0.05;  , P <0.01; , P <0.001 vs. vehicle; ##,P <0.01 vs. entrectinib,N¼ 5; lorlatinib,N¼ 3).C,Kaplan–Meier survival curve of YU1078-luc injectedmice (log-rank
test: n.s., P >0.05;  ,P <0.01 vs. vehicle; ##,P <0.01 vs. entrectinib,N¼ 5; lorlatinib, n¼ 3).D,Representative hematoxylin and eosin (H&E), Ki67, and TUNEL staining
of brain sections following entrectinib and repotrectinib treatments.
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metastases. After receiving 40 mg repotrectinib once daily on the
phase I repotrectinib trial, the patient achieved confirmed PR
(80%) based on RECIST1.1, currently ongoing at 20 months
(Fig. 3A). The phase I repotrectinib trial also included a ROS1þ
lung cancer patient who had recurred under ceritinib. Pre-
repotrectinib brain imaging revealed multiple asymptomatic brain
metastases. This patient tolerated repotrectinib treatment (40–
240 mg, every day) and achieved confirmed RECIST1.1-based PR
(40%) that is ongoing at 16 months (Fig. 3B). As a clinical proof
of concept, the potent intracranial activity of repotrectinib has been
observed in a TKI-naïve patient and a patient who had progressed
on prior TKI enrolled in an ongoing phase I/II clinical trial.
Multiple metastatic brain lesions disappeared after 2-month treat-
ment and were maintained over 15 months in each patient.
Repotrectinib overcomes crizotinib-resistant ROS1G2032R
We identified the ROS1G2032R mutation in YU1079, which was
serially established in the same patient as YU1078 but after
progressing on crizotinib treatment. On the basis of recent studies
examining lorlatinib and cabozantinib in Ba/F3 cells engineered with
CD74–ROS1G2032R (10, 13), we investigated these TKIs in our YU1079
with CD74-ROS1G2032R. Cabozantinib (IC50, 0.111 mmol/L) and repo-
trectinib (IC50, 0.097 mmol/L) effectively inhibited YU1079
ROS1G2032R growth, concomitant with marked reduction in ROS1
and downstream signal phosphorylation (Fig. 4A–C). However, lor-
latinib (IC50, 1.509 mmol/L) was relatively ineffective in inhibiting
YU1079 ROS1G2032R growth, possibly due to a weak inhibitory effect
on phospho-ROS1, ERK, and STAT3, along with persistent phospho-
AKT (Fig. 4C).
The in vivo efficacy of these TKIs was further evaluated in
YU1079 ROS1G2032R PDX model. Consistent with the in vitro
assays, cabozantinib and repotrectinib significantly led to 102.1%
and 90.9% TGI, respectively, compared with 22.7% TGI for
lorlatinib (Fig. 4D). Considering severe treatment-related toxicities
observed in patients receiving cabozantinib (1, 16, 17), we focused
on comparing repotrectinib with clinically available entrectinib
in the PDX model YHIM1047 ROS1G2032R, established from a
CD74-ROS1 patient with NSCLC who progressed on entrectinib.
As expected from the patient's clinical response, entrectinib
failed to inhibit tumor growth whereas repotrectinib treatment
induced 142.8% TGI (Fig. 4E). IHC revealed marked reduction
of phosphorylated STAT3 and Ki67 in repotrectinib-treated
YHIM1047 ROS1G2032R tumors compared with entrectinib and
vehicle (Fig. 4F).
A Baseline 2 months (−60% PR) 15 months (−80% PR)
B Baseline 2 months (−40% PR) 16 months (−40% PR)
Figure 3.
Favorable response to repotrectinib in
ROS1-TKI treatment-naïve and ceritinib-
resistant patients. A, Confirmed partial
response in a CD74-ROS1 NSCLC patient
based on RECIST1.1 of hepatic and brain
metastasis, after treatment with 40 mg
repotrectinib once daily, at 2 months
and 16 months. B, Confirmed partial
response of lung and brain metastasis
in a patient with CD74-ROS1NSCLCwho
progressed on ceritinib, after treatment
with 40mg (increased to 240mg) repo-
trectinib once daily. Red circles and yel-
low arrows indicate areas of metastatic
tumor disease.
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The clinical activity of repotrectinib against ROS1 SFMwas seen in a
49-year-old female ROS1-rearranged patient who progressed after
44 months of crizotinib treatment with an identified CD74-ROS1
G2032R mutation. The patient received 160 mg twice a day repo-
trectinib which induced a confirmed PR (80%) based on RECIST1.1
currently ongoing at 6 months (Fig. 4G). Taken together, these results
suggest that repotrectinib is a promising therapeutic strategy forROS1-
rearranged NSCLC harboring ROS1G2032R.
Genetic alterations in ROS1-rearranged patients who
progressed on repotrectinib
Finally, we investigated genetic mutation status in biopsies of 2
patients who progressed on repotrectinib in clinical trial using targeted
sequencing. Patient A, a 46-year-oldmale with a 20 pack-year smoking
history, was diagnosedwith adenocarcinoma. The patient underwent a
first biopsy before treatment, followed by a second biopsy after
progression on repotrectinib treatment for about 10months (Table 1).
Figure 4.
Antitumor efficacy of repotrectinib
against crizotinib-resistant ROS1 SFM
G2032R. A, Cell viability assay of
CD74-ROS1G2032R–mutant YU1079
treated with ROS1-TKIs for 72 hours.
B, Colony formation assays involved
treatment for 14 days with the indi-
cated dose of ROS1-TKIs; corre-
sponding colony quantification on
the right (ANOVA with Tukey post
hoc test:  , P < 0.05;  , P < 0.001 vs.
crizotinib; #, P < 0.05 vs. cabozanti-
nib). C, Immunoblots of YU1079 after
6 hours treatment with indicated cri-
zotinib, lorlatinib, cabozantinib, and
repotrectinib doses.D, Tumor growth
of YU1079 xenograft in response to
TKI treatment (Kruskal–Wallis with
Dunn post hoc test: n.s., P > 0.05; ,
P < 0.001 vs. vehicle; #, P < 0.05; ###,
P < 0.001 vs. lorlatinib, N¼ 5). Corre-
sponding waterfall plot on the
right represents individual mouse
response. E, Tumor growth of PDX
model YHIM1047 harboring CD74-
ROS1G2032R mutation (N ¼ 5) treated
with entrectinib and repotrectinib.
Corresponding waterfall plot on the
right represents individual mouse
response. F, Representative Ki67 and
pSTAT3 staining of tumor sections
following entrectinib and repotrecti-
nib treatments. Data are mean  SD
or  SE. G, Confirmed partial
response in a CD74-ROS1G2032R–
mutant NSCLC patient who pro-
gressed on crizotinib based on
RECIST1.1, after treatment with
160 mg repotrectinib twice daily, at
2 and 6 months. Red circles indicate
areas of metastatic disease.
Repotrectinib Exhibits Potent Activity in ROS1þ NSCLC
AACRJournals.org Clin Cancer Res; 26(13) July 1, 2020 3293
on September 8, 2020. © 2020 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst April 8, 2020; DOI: 10.1158/1078-0432.CCR-19-2777 
A variant of the ROS1 translocation, CD74-ROS1 fusion, was
detected by targeted sequencing. Mutations in the ROS1 kinase
domain were not detected. Post-repotrectinib tumor biopsy had
mutations in CCND3 (E253Q), TP53 (H178Q&H179Y), and
SMAD4 (E538), which were absent in the corresponding baseline
biopsy (Supplementary Table S1). These mutations occurred at
different variant allele frequencies (VAF), 7%, 53%, and 47%,
respectively. Patient B was a 38-year-old female with adenocarci-
noma with a 10 pack-year smoking history. The patient was
biopsied following progression on repotrectinib after 10 months
of treatment (Table 1). ROS1 fusion partner was identified as
SLC34A2. We identified CEBPA (196_197insHP, VAF 41%),
RB1 (H555R, VAF 45%), ERBB2 (R143Q, VAF 51%), and
TP53 (E171G, VAF 9%) mutations in the post-repotrectinib
tumor biopsy. We were unable to demonstrate the absence of
these mutations in the baseline biopsy due to lack of available
tumor tissue. Altogether, these findings suggest the possibility of
non-ROS1 dominant mechanism as acquired resistance to repo-
trectinib. Further studies are necessary to investigate the functional
role of these mutations to elucidate acquired resistance mechanism
to repotrectinib.
Discussion
In this study, we demonstrated that repotrectinib is a potent next-
generation TKI against ROS1 and ROS1G2032R mutation with remark-
able activity in the CNS. Our findings highlight the potential of
repotrectinib as a first-line therapy in ROS1þ NSCLC as well as those
with G2032R.
Crizotinib is the FDA-approved standard care in ROS1-rearranged
NSCLC with entrectinib emerging as a promising ROS1-TKI recently
approved by the FDA. Ceritinib and lorlatinib have both previously
showed clinical activity in treatment-naïve ROS1þ NSCLC (8, 18). In
particular, lorlatinib is the only recommended TKI after progression
to crizotinib under National Comprehensive Cancer Network
(NCCN) guidelines (19). To our knowledge, repotrectinib exhibited
the most potent in vitro and in vivo activity compared with other
ROS1-TKIs in treatment-naïve YU1078 model (Fig. 1A–D). Despite
comparable activity between repotrectinib and lorlatinib, repotrectinib
was able to persistently and strongly suppress tumor recurrence in
YU1078-derived xenograft model for more than 80 days even after
drug withdrawal (Fig. 1E). Consistent with previous reports (10), our
findings suggest that repotrectinib is a potent ROS1-TKI in the first-
line setting.
CNS metastases remain a major cause of morbidity and
mortality in ROS1-driven NSCLC. Recent reports highlighted
that 36% of ROS1þ patients experience CNS metastasis at base-
line or 50% after crizotinib treatment similar to ALKþ
NSCLC (9). The low brain-to-plasma ratio of crizotinib suggests
that frequent CNS metastasis during crizotinib treatment may be
due to poor BBB penetration and brain exposure (6). For the first
time, we demonstrated superior CNS penetration of repotrectinib
compared with entrectinib in YU1078-luc intracranial tumor
model with significant reduction of metastatic brain lesion and
extensive mouse survival over 100 days (Fig. 2). This was
clinically supported by two CD74-ROS1 NSCLC patient response
data where repotrectinib rapidly regressed tumor and the met-
astatic brain lesion (Fig. 3). Therefore, upfront repotrectinib
therapy could effectively reduce dismal prognosis due to CNS
progression, which might overcome current limitations of first-
line crizotinib.
Acquired resistance to targeted therapy is a major obstacle for
achieving durable response in oncogene-driven NSCLC. Approxi-
mately 50% to 60% of acquired resistance to crizotinib is caused by
on-target mutations, of which G2032R is the most recalcitrant and
commonly observed mutation in ROS1þ patients. Ceritinib, entrecti-
nib, and lorlatinib did not show robust activity against G2032R, as
reported previously (10, 13). Cabozantinib exhibited comparable
activity to repotrectinib but toxicity observed in clinical trials should
be managed further (16). Recently, a novel ROS1/NTRK inhibitor
DS-6051b was reported to have activity against G2032R in preclinical
models but requires validation in the clinical setting (20). Consistent
with previous reports demonstrating the activity of repotrectinib in
BaF3 CD74–ROS1G2032R cell line and xenograft models (10), we
demonstrated prominent antitumor activity of repotrectinib in crizo-
tinib-refractory YU1079 ROS1G2032R and entrectinib-refractory
YHIM1047 ROS1G2032R. This was supported by pronounced tumor
regression in patient with CD74-ROS1 G2032R NSCLC (Fig. 4).
Recently, preliminary results of TRIDENT1 trial reported meaningful
clinical activity and favorable safety profiles of repotrectinib (21, 22).
The confirmed objective response rate (ORR) was 91% in 11 patients
with TKI-naïve ROS1þNSCLC and 39% in 18 TKI-pretreated patients
after repotrectinib. ROS1G2032R patients demonstrated ORR 43%
(n ¼ 3/7). Most adverse events were manageable and grade 1 to 2.
Collectively, repotrectinib is an effective therapy against ROS1þ
NSCLC patients who are TKI-naïve or TKI-refractory harboring
G2032R.
Upfront next-generation TKI therapy prolonged survival
outcome in patients with EGFR-mut and ALK-fusion NSCLC and
have been approved as standard care in these patients (23, 24).
Moreover, a recent study presented that sequential ALK-TKI treat-
ment fosters development of diverse compound mutations, highly
refractory to all available ALK-inhibitors (25). These data implicate
that upfront use of repotrectinib could be able to prevent or delay
the emergence of G2032R and subsequent compound mutations,
potentially improving clinical outcomes. In line with the idea,
G2032R or ROS1 compound mutation was not observed in 2
patients who progressed on first-line repotrectinib in our study
(Supplementary Table S1). Therefore, optimal first-line therapy
could be derived from repotrectinib-based combinations to prevent
both ROS1-dependent and -independent resistance. Potent overall
and intracranial activity, G2032R specificity, and favorable safety
profiles suggest repotrectinib as a promising first-line TKI.
In conclusion, we demonstrated that repotrectinib is a novel, highly
potent, BBB-penetrant next-generation ROS1/TRK/ALK-TKI. Our
findings provide evidence for repotrectinib as an effective first-line
treatment in ROS1þNSCLC and after progression to prior ROS1-TKI.
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